Perry Cook, MD, presents the case of a 76-year-old man with relapsed/refractory follicular lymphoma.
A 76-Year-Old Man With Relapsed/Refractory Follicular Lymphoma
A key opinion leader explains the first-line treatment options for follicular lymphoma and the challenges of treating patients with early disease progression.
A hematologist/oncologist discusses the tazemetostat as a treatment option for patients with relapsed/refractory follicular lymphoma.
Perry Cook, MD, reviews the role of molecular testing and biomarkers in treatment selection in patients with follicular lymphoma.
A hematologist/oncologist provides insights on individualizing second-line therapy for patients with relapsed/refractory follicular lymphoma.
Dr Perry Cook discusses the challenges of treating relapsed/refractory follicular lymphoma in later lines and describes ongoing developments in the treatment landscape.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
Safusidenib Shows Robust, Ongoing Responses in Grade 2 IDH1-Mutant Glioma
4
Sac-TMT Demonstrates Antitumor Activity, Safety in Urothelial Carcinoma
5
